Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.58
$0.035.01%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.09% | -2.53% | -6.23% | -2.38% | -3.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.84% | -26.53% | -27.26% | -22.04% | -17.91% |
| Operating Income | 32.84% | 26.53% | 27.26% | 22.04% | 17.91% |
| Income Before Tax | 31.11% | 24.68% | 27.42% | 23.81% | 21.26% |
| Income Tax Expenses | 102.94% | -19.73% | -18.78% | 15.38% | -65.89% |
| Earnings from Continuing Operations | 31.07% | 24.68% | 27.42% | 23.79% | 21.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.07% | 24.68% | 27.42% | 23.79% | 21.29% |
| EBIT | 32.84% | 26.53% | 27.26% | 22.04% | 17.91% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 56.96% | 50.02% | 49.80% | 44.75% | 41.23% |
| Normalized Basic EPS | 56.98% | 50.02% | 49.80% | 44.76% | 41.20% |
| EPS Diluted | 56.96% | 50.02% | 49.80% | 44.75% | 41.23% |
| Normalized Diluted EPS | 56.98% | 50.02% | 49.80% | 44.76% | 41.20% |
| Average Basic Shares Outstanding | 72.46% | 53.28% | 46.65% | 39.35% | 35.33% |
| Average Diluted Shares Outstanding | 72.46% | 53.28% | 46.65% | 39.35% | 35.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |